The OSIR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OSIR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The OSIR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View OSIR Detailed Price Forecast - CNN Money||View OSIR Detailed Summary - Google Finance|
|View OSIR Detailed Summary - Yahoo! Finance||View OSIR Stock Research & Analysis - Zacks.com|
|View OSIR Trends & Analysis - Trade-Ideas||View OSIR Major Holders - Barrons|
|View OSIR Call Transcripts - NASDAQ||View OSIR Breaking News & Analysis - Seeking Alpha|
|View OSIR Annual Report - CompanySpotlight.com||View OSIR OTC Short Report - OTCShortReport.com|
|View OSIR Fundamentals - TradeKing||View OSIR SEC Filings - Bar Chart|
|View Historical Prices for OSIR - The WSJ||View Performance/Total Return for OSIR - Morningstar|
|View the Analyst Estimates for OSIR - MarketWatch||View the Earnings History for OSIR - CNBC|
|View the OSIR Earnings - StockMarketWatch||View OSIR Buy or Sell Recommendations - MacroAxis|
|View the OSIR Bullish Patterns - American Bulls||View OSIR Short Pain Metrics - ShortPainBot.com|
|View OSIR Stock Mentions - StockTwits||View OSIR Stock Mentions - PennyStockTweets|
|View OSIR Stock Mentions - Twitter||View OSIR Investment Forum News - Investor Hub|
|View OSIR Stock Mentions - Yahoo! Message Board||View OSIR Stock Mentions - Seeking Alpha|
|View Insider Transactions for OSIR - SECform4.com||View Insider Transactions for OSIR - Insider Cow|
|View OSIR Major Holdings Summary - CNBC||View Insider Disclosure for OSIR - OTC Markets|
|View Insider Transactions for OSIR - Yahoo! Finance||View Institutional Holdings for OSIR - NASDAQ|
|View OSIR Stock Insight & Charts - FinViz.com||View OSIR Investment Charts - StockCharts.com|
|View OSIR Stock Overview & Charts - BarChart||View OSIR User Generated Charts - Trading View|
Osiris Appoints Willi Miesch to its Board of Directors, Change in CEO
Posted on Tuesday February 06, 2018
COLUMBIA, Md., Feb. 06, 2018-- Osiris Therapeutics, Inc. is pleased to announce that its Board of Directors, at a Board Meeting on February 6 th, 2018, appointed Mr. Willi Miesch as a Director, upon recommendation ...
Update in Lawsuit for Investors in Osiris Therapeutics, Inc. (NASDAQ: OSIR) Shares Announced by Shareholders Foundation
Posted on Tuesday November 28, 2017
SAN DIEGO, CA / ACCESSWIRE / November 28, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors who purchased NASDAQ: OSIR shares against Osiris Therapeutics, ...
Former Osiris Therapeutics executive pleads guilty to false statements
Posted on Thursday November 02, 2017
A former chief financial officer of biotechnology company Osiris Therapeutics on Thursday pleaded guilty to making false statements to auditors to inflate the company's reported revenue. Philip Jacoby, 65, entered his plea before U.S. District Judge Denise Cote in in Manhattan, while Osiris separately agreed to pay $1.5 million to settle a related civil lawsuit by the U.S. Securities and Exchange Commission, court records showed. As part of the plea, Jacoby and prosecutors agreed that an appropriate sentence under federal guidelines would be four to 10 months in prison and a fine of up to $5 million.
Osiris Therapeutics Sees Stock Bounce Up On Restatement, Omeros Readies for Presentations of its OMR-721 Candidate Drug
Posted on Wednesday March 29, 2017
NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Stocks of both companies rose on future-oriented news for investors. While FDA clinical trials continue, both companies are getting positive news coverage from ...